True Wealth Design’s Akebia Therapeutics AKBA Stock Holding History

True Wealth Design’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$228	Sell	247 -464	-65%	-$499	﹤0.01%	2328
2026 Q2	$811	Buy	711 +665	+1,446%	+$792	﹤0.01%	2059
2026 Q1	$64	Buy	+46	New	+$63	﹤0.01%	2532
2025 Q4	–	Sell	-58	Closed	-$159	–	2564
2025 Q3	$159	Hold	58	–	–	﹤0.01%	2356
2025 Q2	$212	Buy	58 +21	+57%	+$58	﹤0.01%	2054
2025 Q1	$72	Buy	+37	New	+$76	﹤0.01%	2295

Other funds holding AKBA

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Unified Investment Management Atlanta, Georgia $114M AUM 22.27% 1-Year Est. Return

IWN

Independent Wealth Network Urbandale, Iowa $397M AUM 20.36% 1-Year Est. Return

Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return

Northern Lights Advisors Seattle, Washington $192M AUM 14.28% 1-Year Est. Return

Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return

True Wealth Design's AKBA Position: Q3 2026 in Review

True Wealth Design reduced its Akebia Therapeutics (AKBA) stake by 65% in Q3 2026, selling an estimated $499 and leaving 247 shares worth $228. The position accounts for ﹤0.01% of the portfolio, ranked #2328.

True Wealth Design first reported a position in AKBA in Q1 2025 and has held it in 6 quarters since. The position peaked at $811 in Q2 2026. 21 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

True Wealth Design held 247 shares of Akebia Therapeutics worth $228 as of Q3 2026.
True Wealth Design sold 464 Akebia Therapeutics shares in Q3 2026, an estimated $499.
Akebia Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2328 holding.
True Wealth Design first reported a position in Akebia Therapeutics in Q1 2025 and has held it in 6 quarters since.
True Wealth Design's Akebia Therapeutics position peaked at $811 in Q2 2026.
21 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.